Synthetica生物

2023年6月27日

新聞分享這篇文章分享這篇文章提供的兩個證明科技企業家,西蒙Arkell和亞曆克斯·迪金森吸引種子資金,使負責采用人工智能生物製藥行業的專有平台將減輕醫療數據之間的瓶頸和生物製藥的見解拉古納海灘,加利福尼亞州,6月27日2023 / Synthetica生物從一個私人醫療技術公司開發一個企業級、生成人工智能(GenAI)平台,生物製藥,今天宣布正式啟動公司和新資本的種子資金。公司由西蒙•Arkell OLY / MBA和亞曆克斯·迪金森博士醫療技術開拓者已經建立了成功的公司,包括Predixion深鏡頭,Luxtera Helixis, Chromacode。Synthetica生物關注會議需求加速向生物製藥公司提供可操作的知識驅動藥物開發,臨床試驗,和商業活動在一個安全的和有效的方式。Synthetica生物的風險投資是由美德,從AIX參與合資企業,頁麵一個合資企業,額外的戰略投資者。所得資金將支持Synthetica生物平台的發展和擴張。平台將使個人和公司生物製藥行業的可靠和安全地訪問和分析海量數據,當前數據分析技術。管理合夥人的美德,肖恩·Doolan說“我們很自豪能使種子資金和與這一流團隊組成的合作證明企業家深AI /毫升&生物製藥經驗。最近的進步llm創建直接biopharma-specific商業機會和研發應用程序驅動有形價值的任何商業用戶提供實時訪問分析一個簡單的自然語言界麵。Synthetica生物帶來llm的力量來客戶獨特的數據在一個安全的、可伸縮的和實時平台。”The Synthetica Bio team has created a foundational partnership with one of the largest healthcare data providers in the industry. The platform will leverage de-identified data on over 200 million patients to fine-tune models relevant to several verticals including marketing, drug discovery and clinical trials within a pharmaceutical company. In the new era of GenAI, Synthetica Bio is enabling biopharma companies to use AI responsibly, initially serving commercial teams within this sector. Pharma companies spend an estimated $15 billion targeting healthcare providers. Synthetica Bio's solution leverages a series of best-in-class large language models (LLMs) to ingest real-time data streams and make this information directly available to biopharma clients via a natural interface. Through the GenAI-based architecture, the fine-tuned LLMs are designed for real-time data processing that will enable real-time targeting with verified and secure customer data stores. "By democratizing access to insights from healthcare data we enable healthcare information workers to do their job more effectively, and in a more secure manner," said Mr. Arkell, Chief Executive Officer. "Our early partners are already addressing bottlenecks in commercial targeting with our unique 'co-pilot' approach to address the analytics bottlenecks that slow everyone down. While the healthcare data industry is now providing massive data feeds from diverse sources, the analytics remain outdated, necessitating large teams for even basic queries. Our platform will streamline this process while providing data privacy as a key tenet." "Historically, leadership in healthcare data platforms has been achieved by amassing the largest pools of data. We believe that LLMs are disrupting the traditional model and future leadership will be achieved by the platform that is best able to train and reason with these big data pools. Our aim is to make the Synthetica Bio platform the central destination for biopharma companies to rapidly and cost-effectively gain actionable insights into data from any source," added Dr. Dickinson, Executive Chair of Synthetica Bio. About Synthetica Bio Synthetica Bio is a privately held healthcare technology company based in Laguna Beach, California that is developing the next generation of safe and secure generative artificial intelligence (GenAI) solutions for the biopharma industry. The Synthetica Bio platform leverages and optimizes multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to biopharma discovery, clinical, and commercial teams. The platform enables healthcare professionals to rapidly leverage the power of GenAI within compliance of data security standards required by the industry. For more information, please visit the company's website at https://www.syntheticabio.ai/ . Follow the company on LinkedIn . Media Contact: Russo Partners